// App-Quantinova.ai

315 : Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.

Researchers

Presenter

  • Simron Singh

Principal Investigators

  • Roberto Buzzoni

  • Rodney F. Pommier

  • Markus Raderer

  • Jiri Tomasek

  • Harald Lahner

  • Juan W. Valle

  • Maurizio Voi

  • Lida Bubuteishvili-Pacaud

  • Jeremie Lincy

  • Carolin Sachs

  • Natsuko Okita

  • Steven K. Libutti

  • Do-Youn Oh

  • Matthew H. Kulke

  • Jonathan R. Strosberg

  • James C. Yao

  • Marianne E. Pavel

  • Nicola Fazio

Medical Centers

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • IRCCS Istituto Clinico Humanitas, Rozzano, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Oregon Health and Science University, Portland, OR

  • University Klinik f. Innere Medizin I, AKH, Wien, Austria

  • Masaryk Memorial Cancer Institute, Brno, Czech Republic

  • Universitaetsklinikum Essen, Zentrum f. Innere Medizin, Essen, Germany

  • Institute of Cancer Studies, University of Manchester, The Christie Hospital, Manchester, United Kingdom

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • National Cancer Center Hospital, Tokyo, Japan

  • Montefiore Medical Center, Bronx, NY

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Medicine, Moffitt Cancer Center, Tampa, FL

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Charite-Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany

  • Istituto Europeo di Oncologia, Milano, Italy

Locations

  • Canada

  • Italy

  • United States

  • Austria

  • Czech Republic

  • Germany

  • United Kingdom

  • Switzerland

  • Japan

  • Republic of South Korea

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01524783

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved